Spotlight Therapeutics, a startup with a bold vision for delivering CRISPR therapies into the body without the ...
A month after Biogen signaled plans to shift its attention to “ external opportunities ,” it delivered on that ...
Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug ...
Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move ...
The federal government said it 'ran afoul of no statute' when it announced a 15% cap on indirect cost reimbursements for NIH ...
Subsense, a startup building noninvasive technology to communicate with the brain, is launching with $17 million in funding.
Siegfried’s stock dipped by 6% on the Swiss stock exchange Tuesday after reporting a lower-than-expected sales forecast for ...
A biotech based in Vilnius, Lithuania has won the backing of Lux Capital as the startup plots a US expansion in 2025. Lux led ...
Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will ...
A judge in Singapore ordered the freezing of KBP Biosciences’ assets while Novo Nordisk pursues $830 million in damages over claims that it was deceived in a 2023 licensing deal.
Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...
The former head of the FDA on Tuesday criticized the Trump administration’s efforts to lay off recently hired employees who review the safety of medical devices and other products.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results